Last reviewed · How we verify
Oxytocin 100 i.u.
At a glance
| Generic name | Oxytocin 100 i.u. |
|---|---|
| Also known as | Vagoticin |
| Sponsor | PepTonic Medical AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Methods Decreasing Bleeding in Open Myomectomy (PHASE4)
- Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women (PHASE2)
- Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytocin 100 i.u. CI brief — competitive landscape report
- Oxytocin 100 i.u. updates RSS · CI watch RSS
- PepTonic Medical AB portfolio CI